jRCTs053180162已完成不适用
Gene Therapy using Intramuscular Administration of AMG0001 in Patients with Peripheral Arterial Disease (Gene Therapy using Intramuscular Administration of AMG0001 in Patients with Peripheral Arterial Disease)
未提供0 个研究点目标入组 6 人开始时间: 2014年9月24日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 6
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Other
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 20age old over 至 85age old not（—）
- 性别
- All
入选标准
- •Patients who personally give informed consent in writing
- •Patients aged 20 or older but younger than 85
- •Patients who have a stenosis or occlusion in superficial femoral artery, popliteal artery, or artery below the popliteal of the treated limb confirmed by MRA or CTA.
- •The mean ankle pressure is less than 70 mmHg or ABI is not more than 0.6 during the observation period. (However, this shall not apply in the case of Buerger's disease.)
- •Those who have the following clinical symptoms due to stenosis or occlusion.
- •Rest pain (Fontaine III ) VAS is at least 20mm during the observation period
- •Ulcer (Fontaine IV )
- •Patients in whom revascularization in the treated limb is difficult, or patients who are determined that the adaptation is not impossible but there are some risks in surgery
- •Patients showing no symptom of improvement in the treated limb despite the conduct of conventional medical treatment or intervention for more than two weeks in the observation period after obtaining informed consent. The conventional medical treatment or intervention needs to be continued more than two weeks before obtaining the informed consent.
- •Patients who agree to contraception by a sperm passage blocking method until the end of Week 12 of treatment after obtaining informed consent
- •Inpatient, outpatient allowed
排除标准
- •Patients with a necrotized ulcer and/or an ulcer with exposed tendon or bone in the treated or non-treated limb
- •Patients in whom alcohol or drug dependence had been noted 90 days or less before obtaining informed consent
- •Patient with malignant tumor history or merger. Patients with no recurrence of breast cancer more than 10 years, and with no recurrence of all other tumor types before obtaining informed consent, may be enrolled in the clinical research. Patients must been completed the cancer screening tests as defined in the protocol.
- •Patient with serious cardiac, renal or hematological disease, but excluding plateau chronic maintenance dialysis patients.
- •Patients with HIV antigen or antibody positive
- •Patients who underwent revascularization or amputation in the treated or non-treated limb, excluding small incision, necrotomy or onychectomy etc.
- •Patients who underwent sympathectomy or sympathetic block 90 days or less before obtaining informed consent
- •Patients with an invasive infectious disease which is difficult to control with antibiotics
- •Patients with proliferative diabetic retinopathy of untreated or treatment-resistant, or patients with neovascularization-type age-related macular degeneration
- •Patients with diabetic neuropathy (diffuse symmetrical neuropathy)
- •Participation in another clinical trial 30 days or less before obtaining informed consent
- •Past history of gene therapy excluding AMG0001
- •Pregnant or breast-feeding women, women with suspected pregnancy, and women who desire to become pregnant during the clinical research
- •Patients who were judged to be unsuitable for the clinical research by the attending physician
结局指标
主要结局
-
Pain at rest ulcer
次要结局
- Serious adverse events
研究者
相似试验
进行中（未招募）
不适用
Study to evaluate the improvement of leg's circulation through growth hormone (GH) treatment.ower limb critical ischemiaMedDRA version: 18.0Level: LLTClassification code 10023034Term: Ischemia peripheralSystem Organ Class: 100000004866MedDRA version: 18.0Level: LLTClassification code 10058069Term: Critical limb ischemiaSystem Organ Class: 100000004866MedDRA version: 18.0Level: LLTClassification code 10066920Term: Leg ischemiaSystem Organ Class: 100000004866EUCTR2012-002228-34-ESDiego Caicedo Valdés
已完成
1 期
Clinical Study of Therapeutic Angiogenesis Using Hypoxic Preconditioned Peripheral Blood Mononuclear CellsPeripheral arterial occlusive diseaseJPRN-UMIN000018594Yamaguchi University Graduate School of Medicine Department of Surgery and Clinical Science7
已完成
2 期
Angiogenesis Using VEGF-A165/bFGF Plasmid Delivered Percutaneously in No-option CAD Patients; a Controlled TrialCoronary Artery DiseaseNCT00620217National Institute of Cardiology, Warsaw, Poland52
已完成
不适用
Anti-vascular endothelial growth factor therapy for ocular diseases of neovascularizatioretinopathy of prematurity neovascular glaucome vasoproliferative tumor choroidal neovascularizationJPRN-UMIN000027243School of Medicine Toho University20
招募中
1 期
Anti-vascular endothelial growth factor therapy for ocular diseases with neovascularizatiochoroidal neovascularization diabetic retinopathy retinal vein occulusion neovascular glaucoma retinopathy of prematurity central serous chorioretinopathyJPRN-UMIN000011094Kobe University Graduate school of Medicine510